rcca-header
Clinical Trials

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Type of Cancer
Solid Tumor
Phase
Division (Location)
Hackensack, NJ
Study ID
NCT#
Brief Description
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.